Literature DB >> 7859585

Safety of acid-suppressing drugs.

R A Smallwood1, R G Berlin, N Castagnoli, H P Festen, C J Hawkey, S K Lam, M J Langman, P Lundborg, A Parkinson.   

Abstract

There is an extensive literature on the adverse effects of drugs that inhibit gastric acid secretion. This study presents a critical examination of interactions between antisecretory drugs and other compounds, the frequency of serious adverse effects relating to various body systems, the safety of antisecretory drugs in pregnancy, and longer-term safety data from postmarketing surveillance studies. While interactions with some other drugs, alcohol, and certain carcinogens are of potential concern, in practice clinically significant reactions appear to be rare if they occur at all. A small number of major side-effects have been documented, but they occur rarely, and postmarketing surveillance has not detected other longer-term sequelae. Safety of these drugs in pregnancy is not established, as data are so few. It is concluded that antisecretory agents, by comparison with most other classes of drugs, are remarkably well tolerated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7859585     DOI: 10.1007/bf02214872

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  231 in total

1.  Immunomodulatory properties of cimetidine in ARC patients.

Authors:  N H Brockmeyer; E Kreuzfelder; L Mertins; N Chalabi; W Kirch; N Scheiermann; M Goos; E E Ohnhaus
Journal:  Clin Immunol Immunopathol       Date:  1988-07

2.  Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism.

Authors:  C S Reilly; J Biollaz; R P Koshakji; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

3.  Influence of cimetidine and ranitidine on ethanol pharmacokinetics.

Authors:  L K Webster; D B Jones; R A Smallwood
Journal:  Aust N Z J Med       Date:  1985-06

Review 4.  Cimetidine: an immunomodulator.

Authors:  A Kumar
Journal:  DICP       Date:  1990-03

Review 5.  Effect of cimetidine and ranitidine on cardiovascular drugs.

Authors:  A M Baciewicz; F A Baciewicz
Journal:  Am Heart J       Date:  1989-07       Impact factor: 4.749

6.  Cimetidine-induced acute interstitial nephritis.

Authors:  J M Pitone; J J Santoro; R J Biondi; J C Chiesa; A A Pecora
Journal:  Am J Gastroenterol       Date:  1982-03       Impact factor: 10.864

7.  [Ranitidine and cimetidine in the prevention of stress: ulcer hemorrhage a prospective comparative multicenter study].

Authors:  H O Barth; P Berg; G Brunner; H G Dammann; W Friedl; F H Franken; L Greiner; J Groitl; W Möckel; P Müller
Journal:  Langenbecks Arch Chir       Date:  1984

8.  Safety of nizatidine in clinical trials conducted in the USA and Europe.

Authors:  M L Cloud
Journal:  Scand J Gastroenterol Suppl       Date:  1987

9.  Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.

Authors:  K L Rost; H Brösicke; J Brockmöller; M Scheffler; H Helge; I Roots
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

10.  Hyperpyrexia associated with intravenous cimetidine therapy. Report of a case.

Authors:  C M Parenti; J E Hoffman
Journal:  Arch Intern Med       Date:  1986-09
View more
  3 in total

Review 1.  A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy.

Authors:  P Mazzotta; L A Magee
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  The risk of acute pancreatitis associated with acid-suppressing drugs.

Authors:  I A Eland; C H Alvarez; B H Stricker; L A Rodríguez
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.